Ursodeoxycholic AcidThird Party Manufacturing in India

Ursodeoxycholic Acid (UDCA) protects liver cells and promotes bile flow through three synergistic mechanisms.

First, UDCA displaces endogenous hydrophobic and hepatotoxic bile acids from the bile acid pool. As a highly hydrophilic bile acid, it replaces toxic bile acids at the level of the hepatocyte membrane and intracellular organelles, reducing cell membrane damage and preventing mitochondrial permeability transition. This anti-apoptotic effect protects cholangiocytes and hepatocytes from bile acid-induced injury, making it particularly valuable in cholestatic liver diseases.

Second, UDCA stimulates hepatocellular and ductular secretion by promoting the synthesis, targeting, and insertion of key bile acid transport proteins including the bile salt export pump (BSEP) and multidrug resistance-associated protein 2 (MRP2) into the canalicular membrane. This choleretic effect is mediated through calcium-dependent and protein kinase C-alpha signaling pathways, improving bile flow and reducing the retention of toxic substances in the liver.

Third, for gallstone dissolution, UDCA reduces hepatic cholesterol secretion and intestinal cholesterol absorption. It disperses cholesterol as liquid crystals in aqueous bile media, converting cholesterol-precipitating bile to cholesterol-solubilizing bile. This unique mechanism allows gradual dissolution of radiolucent cholesterol gallstones without surgical intervention.

Therapeutic Uses

Ursodeoxycholic Acid is prescribed for the treatment of:

• Primary Biliary Cholangitis (PBC): The only FDA-approved drug for PBC, UDCA improves liver biochemistry, delays histological progression, and prolongs transplant-free survival when administered at 13 to 15 mg per kg per day.
• Cholesterol Gallstone Dissolution: Dissolves radiolucent, non-calcified gallstones less than 20 mm in diameter in patients with functioning gallbladders who are poor surgical candidates or refuse surgery.
• Gallstone Prevention: Prevents gallstone formation in obese patients undergoing rapid weight loss, including those following bariatric surgery.
• Primary Sclerosing Cholangitis (PSC): Used off-label to improve liver biochemistry, although high-dose therapy in advanced disease requires caution.
• Intrahepatic Cholestasis of Pregnancy: Reduces pruritus and improves liver function tests in pregnant women with cholestasis.
• Bile Reflux Gastritis: Relieves symptoms of bile reflux into the stomach following cholecystectomy or gastric surgery.
• Cystic Fibrosis-Associated Liver Disease: Improves bile flow and liver enzyme levels in patients with cystic fibrosis and hepatobiliary involvement.

Why Manufacturers Choose Ursodeoxycholic Acid

UDCA is a high-value hepatobiliary medication with established demand across gastroenterology and hepatology practices worldwide. Its inclusion in major international treatment guidelines for PBC ensures consistent prescription volumes. The molecule's dual role as both a gallstone dissolution therapy and a first-line treatment for autoimmune liver disease creates diversified market demand.

This makes Ursodeoxycholic Acid an attractive molecule for third party manufacturing in India, with significant export opportunities to regulated markets including the US, EU, and Middle East.